相关实验视频

Updated: Jan 14, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

特拉斯图祖马布雷泽特坎:首次获得批准

Sheridan M Hoy¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|October 25, 2025

概括

针对HER2的抗体-药物结合体trastuzumab rezetecan在中国获得了治疗高级非小细胞肺癌的批准. 这标志着对治疗HER2突变肺癌的一个重要里程碑.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

特拉斯图苏马布 (trastuzumab rezetecan) 是一种针对人体表皮生长因子受体2 (HER2) 的抗体-药物结合体.
它是针对各种固体瘤开发的,包括乳腺,结肠直肠,胃,胃食道结腺癌和肺癌.
江苏恒瑞医药有限公司是这种治疗剂的开发商.

研究的目的:

总结一下trastuzumab rezetecan的发展里程碑.
为了突出该药物的首次监管批准.
为了记录导致批准非小细胞肺癌治疗的旅程.

主要方法:

发展数据和监管提交的审查.
对临床试验结果的分析 (隐含).
药物作为抗体-药物结合物的作用机制的概述.

主要成果:

特拉斯图祖马布雷泽特坎在2025年5月获得了中国国家医药品管理局的批准.
批准是针对具有不可切割的局部晚期或转移性非小细胞肺癌 (NSCLC) 的成年人.
患者必须具有HER2 (ERBB2) 激活突变,并且之前至少接受过一次全身治疗.

结论:

批准代表了针对NSCLC的向治疗的重大进展.
特拉斯图祖马布 (trastuzumab rezetecan) 为特定部分肺癌患者提供了一种新的治疗选择.
这一里程碑标志着药物的成功开发和监管验证.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...